119th Congress · introduced in the Senate · Feb 24, 2025
PLASMA Act
Official title from Congress.gov
Latest action (Feb 24, 2025): Read twice and referred to the Committee on Finance.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in Senate (Feb 24, 2025)
Preserving Life-saving Access to Specialty Medicines in America Act or the PLASMA Act
This bill phases-in certain price adjustments for plasma-derived products under the Medicare prescription drug benefit's Manufacturer Discount Program.
Current law requires manufacturers of covered drugs under the Medicare prescription drug benefit to provide a 10% discount for covered drugs during the initial coverage phase (i.e., before a beneficiary reaches the out-of-pocket spending threshold) and a 20% discount during the catastrophic coverage phase (i.e., after a beneficiary reaches the out-of-pocket spending threshold).
The bill phases-in discounts for plasma-derived products over several years, starting with a 1% discount in 2026 for both the initial and catastrophic coverage phases, and ending with a 10% discount beginning in 2030 for the initial coverage phase and a 20% discount beginning in 2032 for the catastrophic coverage phase.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Finance.
Introduced in Senate
Actions from Congress.gov, newest first.
Blood and blood diseases · Drug therapy · Health care costs and insurance · Manufacturing · Medicare · Prescription drugs
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
31 citations; showing the 25 most recently posted.
CSL BEHRING LLC · lobbying firm or registrant: SPLITOAK STRATEGIES LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$40,000
Paid to lobbying firm
H.R.1476/S.694, PLASMA Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: THE NICKLES GROUP, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to drug shortages. Monitored im…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$360,000
Spent on own lobbying
H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medica…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: SPLITOAK STRATEGIES LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$40,000
Paid to lobbying firm
H.R.1476/S.694, PLASMA Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: THE NICKLES GROUP, LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Health Issues
$370,000
Spent on own lobbying
H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medica…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: SPLITOAK STRATEGIES LLC
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Medicare/Medicaid
$40,000
Paid to lobbying firm
H.R.1476/S.694, PLASMA Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: THE NICKLES GROUP, LLC
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 16, 2026 · issue area: Health Issues
$480,000
Spent on own lobbying
H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medica…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: HARBINGER STRATEGIES, LLC
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 21, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
The PLASMA Act (H.R.1476/S.694): issues related to Part D and plasma-derived therapies.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: SPLITOAK STRATEGIES LLC
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Medicare/Medicaid
$40,000
Paid to lobbying firm
H.R.1476/S.694, PLASMA Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: THE NICKLES GROUP, LLC
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · lobbying firm or registrant: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under th…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 18, 2026 · issue area: Health Issues
$470,000
Spent on own lobbying
H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under th…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: HARBINGER STRATEGIES, LLC
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 21, 2025 · issue area: Health Issues
$50,000
Paid to lobbying firm
The PLASMA Act (H.R.1476/S.694): issues related to Part D and plasma-derived therapies.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: THE NICKLES GROUP, LLC
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: SPLITOAK STRATEGIES LLC
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Medicare/Medicaid
$40,000
Paid to lobbying firm
H.R.1476/S.694, PLASMA Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 17, 2025 · issue area: Health Issues
$450,000
Spent on own lobbying
H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under th…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · lobbying firm or registrant: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 16, 2025 · issue area: Health Issues
$80,000
Paid to lobbying firm
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under th…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TAKEDA PHARMACEUTICALS AMERICA INC · lobbying firm or registrant: TAKEDA PHARMACEUTICALS AMERICA, INC.
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · amended · posted Aug 26, 2025 · issue area: Health Issues
$1,570,000
Spent on own lobbying
…ation/International Reference Pricing Issues related to rare disease diagnosis and access to care Issues related to Pharmacy Benefit Managers (PBMs) H.R. 1476, S. 694, PLASMA Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: HARBINGER STRATEGIES, LLC
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Health Issues
$50,000
Paid to lobbying firm
The PLASMA Act (H.R.1476/S.694): issues related to Part D and plasma-derived therapies.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: SPLITOAK STRATEGIES LLC
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Medicare/Medicaid
$40,000
Paid to lobbying firm
H.R.1476/S.694, PLASMA Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CSL BEHRING LLC · lobbying firm or registrant: THE NICKLES GROUP, LLC
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 18, 2025 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · lobbying firm or registrant: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 16, 2025 · issue area: Health Issues
$80,000
Paid to lobbying firm
H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under th…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 16, 2025 · issue area: Health Issues
$390,000
Spent on own lobbying
H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under th…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing